Monopar Therapeutics (MNPR) research

Monopar Therapeutics
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$89.38
As of

Monopar Therapeutics (MNPR): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-12.

As of . Source: SEC EDGAR filings for MNPR. Method and limitations.

SHARE THIS CARD

Share the MNPR intelligence card

A branded snapshot of MNPR: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion MNPR intelligence card preview
Post to X
LIVE TERMINAL

See MNPR live in the terminal

Track MNPR's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live MNPR terminal, free

Active signals for MNPR

FREE, NO ACCOUNT

Every signal on MNPR, as it fires

You are seeing 5 of 8 signals recorded on MNPR since 2026-05-24.

The five above landed across 4 days. The other 3 were recorded on those same days. 4 of the 8 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in MNPR (2026Q2)

Manager / securityMarket value% portfolioQoQ
MILLENNIUM MANAGEMENT LLCCUSIP 61023L207 · 2026Q2$4.7M0.00%,
CITADEL ADVISORS LLCCUSIP 61023L207 · 2026Q2$3.4M0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP 61023L207 · 2026Q2$1.1M0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, MNPR

MNPR against its peers

MNPR's return on equity of -10.0% ranks in the 76th percentile of 18 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.

MetricMNPRPeer medianPercentilen
Revenue FY0.0 USD10.8M USD1315
Operating marginn/a-59.1%n/a13
Net marginn/a-66.0%n/a13
Return on equity-10.0%-48.7%7618

Peers (20): NGNE, CTMX, ALT, CBIO, AURA, VSTM, PHAT, VALN, SGMT, STTK, MDXG, CRMD, ALLO, XOMA, NVCT, IRWD, ZVRA, EPRX, PRME, OCS. Left out: BLSM (no annual filing), SCTX (no annual filing), AGMB (no annual filing), DRUG (period gap), EIKN (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (MNPR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more MNPR signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to MNPRand get the insider, 13F, options, and confluence read in one view.

Open the live MNPR terminal, free